Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: February 22, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 948 miles
GSK Investigational Site
Denver,CO

VISITS: Number of visits unavailable

PHASE: I

NCT ID: NCT02783300

Targeted Therapy GSK3326595 for Advanced HER2- Breast (and Other) Cancers

A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma Scientific Title

Purpose
To assess the safety, effects (good and bad) and best dose of an experimental targeted therapy called GSK3326595 that blocks a protein called arginine methyltransferase 5.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) breast cancer that is either triple negative (ER-, PR-, HER2-) or hormone positive (ER+ or PR+) and HER2 negative, has progressed on a prior therapy, and, if hormone sensitive, has been treated with a CDK 4/6 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">GSK3326595, by mouth, daily</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">This study will assess the safety, effects (good and bad) and best dose of an experimental targeted therapy called GSK3326595 that blocks a protein called arginine methyltransferase 5. </li> <li class="seamTextUnorderedListItem">This study is also enrolling people with other types of cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02783300' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/protein-arginine-methyltransferase-5-inhibitor-gsk3326595' target='_blank'>NCI Drug Dictionary: GSK3326595</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy?fbclid=IwAR3gFr1adHefp7nRg997kYNvNM6g5sH8qJc3ko5tlY2DoGAtfFa_rRp8H9k' target='_blank'>ASCO: Understanding Targeted Therapy</a> </li></ul>
See more